STOCK TITAN

Zomedica Corp. - ZOM STOCK NEWS

Welcome to our dedicated page for Zomedica news (Ticker: ZOM), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.

Zomedica Corp. (NYSE American: ZOM) is a veterinary health company based in Ann Arbor, Michigan, focused on creating innovative products for companion animals, including dogs, cats, and horses. The company addresses the unmet needs of clinical veterinarians through its diverse product portfolio that includes diagnostic and therapeutic devices aimed at enhancing both patient and practice health.

Core Business:
Zomedica specializes in the development and commercialization of veterinary diagnostic tools and pharmaceutical products. Their flagship product, the TRUFORMA® platform, uses Bulk Acoustic Wave (BAW) technology to offer highly sensitive and accurate point-of-care diagnostics for thyroid and adrenal disorders in dogs and cats. The TRUFORMA system empowers veterinarians to make timely and precise diagnostic decisions directly within their clinics, eliminating the delays associated with sending samples to external laboratories.

Recent Achievements:
Recently, Zomedica has expanded its intellectual property portfolio to include 188 patents and 131 trademarks, offering robust protection for its innovative products. This portfolio includes newly issued patents that enhance the TRUFORMA system's capability to detect a wider array of health conditions.

Current Projects:
The company is working on expanding its product range and market reach. The recent CE certification for the VetGuardian® remote contactless monitoring system paves the way for Zomedica's expansion into the European veterinary market. Additionally, the company has launched an improved canine cortisol assay and Over-the-Air (OTA) software update capabilities for the TRUFORMA platform, making it easier for veterinarians to access the latest diagnostic tools and features.

Financial Condition:
For the first quarter of 2024, Zomedica reported a 14% increase in revenue to $6.3 million, driven by growth in both its diagnostic and therapeutic segments. The company's gross margin stood at 66%, and it holds $90.9 million in cash and available-for-sale securities as of March 31, 2024.

Market Position:
With an estimated total addressable market of $2.5 billion annually for its diagnostic and therapeutic products, Zomedica is well-positioned to capture significant market share. The company's potential customer base includes approximately 4,450 equine or mixed veterinary practices and 30,000 small animal veterinary practices in the United States alone.

Partnerships and Collaborations:
Zomedica collaborates with veterinary researchers to advance animal healthcare through continuous innovation. The company's recent expansion of its global manufacturing and distribution facilities in Roswell, Georgia, aims to support the growing demand for its products.

For more information, visit www.zomedica.com

Rhea-AI Summary
Zomedica Corp. reports Q1 2023 financial results with revenue of $5.5 million, a 45% increase compared to Q1 2022. Gross margin was 70%. The company ended Q1 with $147.5 million in cash. Zomedica plans to introduce new product platforms in 2023 and evaluate strategic business opportunities in the animal health sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
-
Rhea-AI Summary
Zomedica Corp. has exercised its option to acquire Structured Monitoring Products, Inc. (SMP), the makers of VetGuardian™ zero-touch vital signs remote monitoring system. The acquisition is based on Zomedica's previous investments in SMP. The VetGuardian system allows real-time remote monitoring of pets' vital signs without wired leads or a harness. Zomedica has been distributing the VetGuardian system since January 2023 and is expanding its launch through U.S. animal health distributors. The acquisition will involve a non-refundable deposit of $250 thousand and a definitive agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM), a veterinary health company, announced that CEO Larry Heaton will provide a strategic update at the H.C. Wainwright Global Investment Conference on May 2, 2023, at 2:30 PM ET. This presentation will be available via webcast and can be accessed on Zomedica's website after the event.

Zomedica specializes in point-of-care diagnostics and therapeutic products for companion animals, such as dogs and cats. Their mission focuses on enhancing productivity and revenue for veterinarians while improving animal care. For more information about their products, visit www.zomedica.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
conferences
-
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) is set to be featured on The RedChip Money Report airing on Bloomberg TV on April 1, 2023, at 7 p.m. ET. This interview aims to provide insights into Zomedica's operations in the veterinary health sector, focusing on products for clinical veterinarians and enhancing animal care. The show, with an estimated reach of 73 million homes in the U.S., is part of RedChip Companies' effort to highlight microcap and small-cap stocks.
For complete access to the interview, visit here.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
-
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) announced the appointment of Peter L. Donato as its new Chief Financial Officer, effective March 16, 2023. With over 30 years of experience primarily in the human health sector, Donato's background includes significant roles such as CFO and CEO. He previously led a consulting practice focusing on public company readiness and served as CFO at Standard Bariatrics. Donato succeeds Ann Marie Cotter, who is retiring after contributing significantly to the company. Zomedica emphasizes that Donato's diverse expertise will support the company's growth and enhance care for companion animals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.45%
Tags
management
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) reported significant growth in its 2022 financial results, with revenue surging to $18.9 million, a 361% increase from 2021. This growth is attributed to the full-year impact of the PulseVet platform and the recently acquired Assisi products, contributing combined revenues of $18.5 million.

Gross margin stood at 72%, with a net loss of $17.0 million, slightly improved from the previous year. Zomedica ended 2022 with $156 million in liquidity and plans to expand its product offerings with new launches in 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
-
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) will host a conference call on March 15, 2023, at 4:30 p.m. ET to discuss operational and financial highlights for the fourth quarter and fiscal year ended December 31, 2022. Interested parties can join the live call at +1-877-407-0789 (U.S. Toll-Free) or via webcast. A replay of the call will be available until March 29, 2023. Zomedica focuses on creating innovative diagnostic and therapeutic products for companion animals, aiming to enhance veterinary practices.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.01%
Tags
conferences earnings
-
Rhea-AI Summary

Zomedica Corp. (NYSE American: ZOM) reported preliminary unaudited results for Q4 and the full year 2022. Q4 revenue is expected to be approximately $6.0-$6.2 million, marking an increase of 46-51% year-over-year, driven by PulseVet sales and the addition of Assisi products. For the full year, revenue is projected at $18.6-$18.9 million, reflecting a 354-361% increase from the previous year. The company anticipates a gross margin of about 72% for 2022. As of December 31, 2022, Zomedica expects to have approximately $156 million in cash and equivalents. The company plans to launch new products in 2023, including the VetGuardian monitor and the TRUVIEW microscopy platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
none
Rhea-AI Summary

Zomedica Corp. (NYSE American:ZOM) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on February 11, 2023, at 7 p.m. ET. The interview, which aims to enhance awareness of Zomedica's veterinary health initiatives, showcases insights from CEO Larry Heaton on improving pet care and creating new opportunities for veterinarians. The program is accessible to approximately 73 million households in the U.S. Zomedica is committed to addressing unmet needs in veterinary services with innovative diagnostic and medical products designed to boost veterinarian productivity and animal health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
none

FAQ

What is the current stock price of Zomedica (ZOM)?

The current stock price of Zomedica (ZOM) is $0.1253 as of December 20, 2024.

What is the market cap of Zomedica (ZOM)?

The market cap of Zomedica (ZOM) is approximately 118.5M.

What does Zomedica Corp. specialize in?

Zomedica Corp. specializes in the development and commercialization of diagnostic and therapeutic products for companion animals.

What is the TRUFORMA® platform?

The TRUFORMA® platform is a point-of-care diagnostic system that uses Bulk Acoustic Wave (BAW) technology to provide highly sensitive and accurate diagnostics for thyroid and adrenal disorders in dogs and cats.

Where is Zomedica Corp. based?

Zomedica Corp. is based in Ann Arbor, Michigan.

What recent milestones has Zomedica achieved?

Zomedica has expanded its intellectual property portfolio to include 188 patents and 131 trademarks. The company has also received CE certification for its VetGuardian® remote contactless monitoring system.

What financial performance did Zomedica report for Q1 2024?

For Q1 2024, Zomedica reported a 14% increase in revenue to $6.3 million and a gross margin of 66%. The company has $90.9 million in cash and available-for-sale securities as of March 31, 2024.

What is the market potential for Zomedica's products?

The total addressable market for Zomedica's diagnostic and therapeutic products is estimated at $2.5 billion annually.

What are some of Zomedica’s key products?

Key products include the TRUFORMA® diagnostic platform, VetGuardian® remote monitoring system, and PulseVet® therapeutics, among others.

What is the significance of the CE certification for VetGuardian®?

The CE certification for VetGuardian® confirms that the product meets EU health, safety, and environmental protection standards, allowing Zomedica to expand its market reach into Europe.

How does Zomedica support veterinarians?

Zomedica provides veterinarians with innovative diagnostic and therapeutic tools that enhance patient care and operational efficiency, enabling timely and accurate treatment decisions.

How can I get more information about Zomedica?

For more information, visit Zomedica's official website at www.zomedica.com.

Zomedica Corp.

NYSE:ZOM

ZOM Rankings

ZOM Stock Data

118.48M
961.51M
1.78%
8.33%
5.12%
Medical Devices
Pharmaceutical Preparations
Link
United States of America
ANN ARBOR